弥漫性中线胶质瘤的细胞免疫治疗现状  

Treatment Current Status of Cellular Immunotherapy for Diffuse Midline Glioma

作　　者：王燚 孙涛[2] WANG Yi;SUN Tao(School of Biological Science and Medical Engineering,Beihang University,Beijing 100191,China;不详)

机构地区：[1]北京航空航天大学生物与医学工程学院,北京100191 [2]首都医科大学附属北京天坛医院

出　　处：《中国医学创新》2023年第30期185-188,共4页Medical Innovation of China

基　　金：北京市自然科学基金(Z190015)。

摘　　要：弥漫性中线胶质瘤(diffuse midline glioma,DMG)是好发于儿童脑干的高度侵袭性且致命的肿瘤。此类肿瘤手术难度大且预后较差,潜在肿瘤生物学研究和大量临床试验几乎未改变其预后。持续开发新的、有效的DMG治疗方案仍是一个重要的研究领域。鉴于DMG不适合手术切除,对放疗的反应有限,且对传统化疗无效,细胞免疫疗法已成为一种有前途的替代治疗方式。本综述总结了DMG细胞免疫治疗方法及其局限性,为临床前和早期临床试验数据转化为DMG患者有效标准化治疗所提供思路及参考。Diffuse midline glioma(DMG)is a highly aggressive and fatal tumor that occurs in the brain stem of children.This type of tumor is difficult to operate and has a poor prognosis,and studies of underlying tumor biology and numerous clinical trials have hardly changed its prognosis.The ongoing development of new and effective DMG treatment regiments remains an important area of research.Given that DMG is not suitable for surgical removal,has a limited response to radiation,and is ineffective against conventional chemotherapy,cellular immunotherapy has emerged as a promising alternative treatment modality.This review summarizes DMG cellular immunotherapy and their limitations,and provides ideas and references for translating preclinical and early clinical trial data into effective standardized treatment for DMG patients.

关 键 词：弥漫性中线胶质瘤 过继细胞转移 细胞免疫疗法 

分 类 号：R739.4[医药卫生—肿瘤]